These transcriptional signatures are mainly involved in immune regulation (CEBPB, STAT3, and JAK2), metabolism (PPARGC1 and MTOR), cell cycle (CDK1), and apoptosis (BCL2), suggesting that the deregulation of these pathways in CTS may contribute to the altered prognosis in colon cancer. This evidence concerns the gene MTOR and malignant colon neoplasm.